Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 4/20 | 0.40 |
| ▸ | TSPO | P30536 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6778001 | 0.92 | TSPO (0.43) | CNR2TSPOKMT2APPARGLMNA | |
| SCHEMBL6777596 | 0.87 | CNR2 (0.38) | CNR2CYP2C19CNR1TSPOKMT2A | |
| SCHEMBL28301396 | 0.83 | CYP2C19 (0.61) | CNR2CYP2C19CNR1TSPOPPARG | |
| SCHEMBL6780662 | 0.81 | TSPO (0.40) | CNR2TSPOPPARGLMNAPOLB | |
| SCHEMBL6778743 | 0.78 | PPARA (0.54) | KMT2APPARGLMNAPOLBTP53 | |
| SCHEMBL6486223 | 0.78 | NR1H2 (0.54) | LMNA | |
| SCHEMBL17700288 | 0.76 | TSHR (0.54) | CNR2CYP2C19TSPOPPARGLMNA | |
| SCHEMBL6775198 | 0.76 | CYP2C19 (0.41) | CNR2CYP2C19CNR1TSPOKDM1A | |
| SCHEMBL6778816 | 0.76 | PPARA (0.46) | CYP2C19PPARGLMNAPOLBMAPT | |
| SCHEMBL4457891 | 0.76 | BLM (0.47) | KMT2APPARGRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176445-A1 | Propionic acid derivatives | BAYER PHARMACEUTICALS CORPORATION | 2004-09-09 | — | — | US | disclosed |
| US-6750236-B2 | CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-15 | — | — | US | disclosed |
| US-20030187041-A1 | Propionic acid derivatives | URBAHNS KLAUS (DE) | 2003-10-02 | — | — | US | disclosed |
| US-6548538-B2 | Potent peroxisome proliferator activated receptor (PPAR)-alpha-activating compounds; propionic acid 2-subsituted with an N-(phenylaminocarbonylalkyl), N-(2-furanylmethyl)aminoalkylphenyl group | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-15 | — | — | US | disclosed |
| US-20030032671-A1 | Propionic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187041-A1 | Propionic acid derivatives | PPARA, PPARD, PPARG | CNR2 287/4885CYP2C19 1392/4885CNR1 340/4885 |
| US-20030032671-A1 | Propionic acid derivatives | PPARD, PPARA, PPARG | CNR2 511/4885CYP2C19 2278/4885CNR1 572/4885 |
| US-20040176445-A1 | Propionic acid derivatives | PPARD, PPARA, PPARG | CNR2 511/4885CYP2C19 2278/4885CNR1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.